MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584719 | Name: Encainide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Encainide is an ANTI-ARRHYTHMIA AGENT that blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.

Chemical Structure

Encainide
Encainide
CAS#66778-36-7

Theoretical Analysis

MedKoo Cat#: 584719

Name: Encainide

CAS#: 66778-36-7

Chemical Formula: C22H28N2O2

Exact Mass: 352.2151

Molecular Weight: 352.48

Elemental Analysis: C, 74.97; H, 8.01; N, 7.95; O, 9.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Encainide; MJ 9067
IUPAC/Chemical Name
Benzamide, 4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, (+-)-
InChi Key
PJWPNDMDCLXCOM-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
SMILES Code
O=C(NC1=CC=CC=C1CCC2N(C)CCCC2)C3=CC=C(OC)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 352.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8. PubMed PMID: 1900101. 2: Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989 Aug 10;321(6):406-12. PubMed PMID: 2473403. 3: Hilleman DE, Mohiuddin SM, Destache CJ, Stoysich AM, Nipper HC, Malesker MA. Impact of food on the bioavailability of encainide. J Clin Pharmacol. 1992 Sep;32(9):833-7. PubMed PMID: 1430302. 4: Roden DM, Woosley RL. Clinical pharmacokinetics of encainide. Clin Pharmacokinet. 1988 Mar;14(3):141-7. Review. PubMed PMID: 3131058. 5: Harrison DC, Kates RE, Quart BD. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide. Am J Cardiol. 1986 Aug 29;58(5):66C-73C. PubMed PMID: 3092622. 6: Antonaccio MJ, Gomoll AW, Byrne JE. Encainide. Cardiovasc Drugs Ther. 1989 Oct;3(5):691-710. Review. PubMed PMID: 2518680. 7: Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J Am Coll Cardiol. 1991 Aug;18(2):356-65. PubMed PMID: 1906902. 8: Salerno DM, Fifield J, Krejci J, Hodges M. Encainide-induced hyperglycemia. Am J Med. 1988 Jan;84(1):39-44. PubMed PMID: 3122563. 9: Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation. 1994 Dec;90(6):2843-52. PubMed PMID: 7994829. 10: Furlanello F, Vergara G, Bettini R, Mosna G, Gramegna L, Disertori M. Flecainide and encainide. Eur Heart J. 1987 Mar;8 Suppl A:33-40. Review. PubMed PMID: 3107989. 11: Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review. PubMed PMID: 19817501. 12: Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Béréziat G, Jaillon P. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther. 1992 Nov;263(2):780-6. PubMed PMID: 1432700. 13: Carmeliet E. Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibers and on the Langendorff-perfused guinea-pig heart. Eur J Pharmacol. 1980 Feb 8;61(3):247-62. PubMed PMID: 6767615. 14: Markel ML, Prystowsky EN, Heger JJ, Miles WM, Fineberg N, Zipes DP. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. Am J Cardiol. 1986 Aug 29;58(5):41C-48C. PubMed PMID: 3092619. 15: Kazierad DJ, Lalonde RL, Hoon TJ, Mirvis DM, Bottorff MB. The effect of diltiazem on the disposition of encainide and its active metabolites. Clin Pharmacol Ther. 1989 Dec;46(6):668-73. PubMed PMID: 2513160. 16: Kreeger RW, Hammill SC. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc. 1987 Nov;62(11):1033-50. Review. PubMed PMID: 3118116. 17: Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther. 1989 Apr;249(1):134-42. PubMed PMID: 2496225. 18: Pool PE. Treatment of supraventricular arrhythmias with encainide. Am J Cardiol. 1986 Aug 29;58(5):55C-57C. Review. PubMed PMID: 3092621. 19: Lee JH, Rosen MR. Use-dependent actions and effects on transmembrane action potentials of flecainide, encainide, and ethmozine in canine Purkinje fibers. J Cardiovasc Pharmacol. 1991 Aug;18(2):285-92. PubMed PMID: 1717791. 20: Wensing G, Mönig H, Ohnhaus EE, Hoensch HP. Pharmacokinetics of encainide in patients with cirrhosis. Cardiovasc Drugs Ther. 1991 Aug;5(4):733-9. PubMed PMID: 1909559.

View History

BP Fluor 488 Hydroxylamine

BP Fluor 488 Hydroxylamine

Featured